logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Mohamed Bouattour

liver cancer and innovation therapy unit
H指数:36
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

度伐利尤单抗和特瑞普利单抗，联合或不联合伦伐替尼，与经动脉化疗栓塞联合用于栓塞适应证的肝细胞癌患者（EMERALD-3）：一项全球、随机、开放标签、申办者设盲的III期研究

Lancet Oncology
IF35.9
2026-08-240
PRE
Masatoshi Kudo; Ghassan K Abou-Alfa; Zhenggang Ren; Jeong Heo; Riccardo Lencioni; Yasuaki Arai; Mohamed Bouattour; Maria A Gonzalez-Carmona; Yabing Guo; Ai-Bing Xu; Gustavo Vasconcelos Alves; Arunee Dechaphunkul; Gwo Fuang Ho; Yueh Ni Lim; HongTao Hu; Ruibao Liu; Shanzhi Gu; Vikas Ostwal; Witsarut Manasirisuk; Chang-Fang Chiu
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study

度伐利尤单抗联合吉西他滨为基础的化疗方案在晚期胆道癌中的应用：TOURMALINE IIIb期研究的主要结果

Journal of Hepatology
IF33
2026-07-060
OAAI
Do-Youn Oh; Masafumi Ikeda; Teresa Macarulla; Aiwu Ruth He; Joon Oh Park; Masayuki Kitano; Guido Giordano; Kyu-pyo Kim; Thomas Wirth; David Tai; Mohamed Bouattour; Tiziana Pressiani; Farshid Dayyani; Angela Lamarca; Ugochinyere Emeribe; Susanne Radke; Peng Sun; Boris Baur; Arndt Vogel
Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort

免疫治疗时代下肝癌的二线治疗实践：CHIEF队列

JHEP Reports
IF7.5
2026-06-120
OAAI
Marie DECRAECKER; Héloïse BOURIEN; Elhadji Malick THIAM; Julien EDELINE; Alice KOUDJOU-SONEGUENG; Philippe MERLE; Jean-Frédéric BLANC; Giuliana AMADDEO; Thomas UGUEN; Thomas DECAENS; Nathalie GANNE-CARRIE; Christine SILVAIN; Mohamed BOUATTOUR; Ghassan RIACHI; Manon ALLAIRE; Stéphane CATTAN; Xavier ADHOUTE; Marilyne GRATIEN; Rodolphe ANTY; Jean-Marie PERON
Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma

Child-Pugh B肝细胞癌患者对阿替利珠单抗-贝伐珠单抗反应的临床预测因子

JHEP Reports
IF7.5
2026-06-110
OAAI
Anne Victoire Odent; Claudia Campani; Mohamed Bouattour; Yann Touchefeu; Victoria Delhoume; Olivier Rosmorduc; Alina Pascale; Jihyun An; Han Chu Lee; Hélène Regnault; Dominique Thabut; Giuliana Amaddeo; Massih Ningararhi; Isabelle Olivier-Hourmand; Chloe Metivier; Maxime Ronot; Line Ntandja-Wandji; Violaine Ozenne; Sabrina Sidali; Fabio Marra
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

“A-B-C”分类揭示了atezolizumab/bevacizumab治疗下肝细胞癌患者的结局轨迹

Clinical Gastroenterology and Hepatology
IF12
2025-11-250
OAAI
Claudia Campani; Clelia Galvanin; Ju Hyun Shim; Mohamed Bouattour; Yann Touchefeu; Victoria Delhoume; Olivier Rosmorduc; Alina Pascale; Jihyun An; Han Chu Lee; Helene Regnault; Dominique Thabut; Valérie Paradis; Julien Calderaro; Marianne Ziol; Aurélie Beaufrère; Alexandre Sayadi; Giuliana Amaddeo; Manon Allaire; Isabelle Olivier-Hourmand
Self-supervised learning to predict intrahepatic cholangiocarcinoma transcriptomic classes on routine histology

利用自监督学习预测肝内胆管癌转录组学类别在常规组织学中的应用

JHEP Reports
IF7.5
2025-11-110
OAAI
Aurélie Beaufrère; Tristan Lazard; Rémy Nicolle; Gwladys Lubuela; Jérémy Augustin; Miguel Albuquerque; Baptiste Pichon; Camille Pignolet; Victoria Priori; Nathalie Théou-Anton; Mickael Lesurtel; Mohamed Bouattour; Kévin Mondet; Jérôme Cros; Julien Calderaro; Thomas Walter; Valérie Paradis
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study

卡博替尼用于肝细胞癌的真实世界实践（CLERANCE）：一项前瞻性、干预性研究

LIVER CANCER
IF9.1
2025-11-010
OA
Villeret, Francois; Bouattour, Mohamed; Blanc, Jean-Frederic; Peron, Jean-Marie; Debette-Gratien, Marilyne; Nahon, Pierre; Nguyen Khac, Eric; Phelip, Jean-Marc; Assenat, Eric; Bourgeois, Vincent; Richou, Carine; Heurgue, Alexandra; Bronowicki, Jean-Pierre; Ollivier-Hourmand, Isabelle; Uguen, Thomas; Cattan, Stephane; Thevenon, Sylvie; Boucheny, Camille; Guilloreau, Paule; Pradat, Pierre; Merle, Philippe
Real-World Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort

阿特珠单抗–贝伐珠单抗在肝细胞癌中的真实世界结局：法国前瞻性CHIEF队列研究

Liver International
IF5.2
2025-09-040
OAAI
Manon Allaire; Elhadji Malick Thiam; Guiliana Amaddeo; Mohamed Bouattour; Julien Edeline; Bleuenn Brusset; Marianne Ziol; Philippe Merle; Jean Frédéric Blanc; Thomas Uguen; Nathalie Ganne; Stéphane Cattan; Ghassan Riachi; Véronique Loustaud-Ratti; Thomas Decaens; Christine Silvain; Jean Marie Peron; Aurore Baron; Georges Philippe Pageaux; Frédéric Oberti; Rodolphe Anty; Alina Pascale; Sylvain Manfredi; Marc Bourliere; Jean Baptiste Nousbaum; Alexandra Heurgue; Isabelle Ollivier-Hourmand; Marie Lequoy; Jean Pierre Bronowicki; Anne Laure Villing; Gerard Ducournau; Olivier Ganry; Charlotte Costentin; Eric Nguyen-Khac
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data

一项多中心国家II期临床试验，评估Tislelizumab单药治疗Child-Pugh B级和ALBI 1级或2级肝功能评分的肝细胞癌患者的疗效：UCGI 41 HESTIA试验设计与初步安全性数据

Digestive and Liver Disease
IF3.8
2025-08-050
PRE
Héloïse Bourien; Xavier Adhoute; Boris Campillo-Gimenez; Mohamed Bouattour; Eric Assenat; Pierre Nahon; Simon Launay; Frédéric Oberti; Antonio Saviano; Thomas Decaens; Philippe Merle; Alexandre Harlé; Thierry Lecomte; David Ternant; Laure Monard; Veronica Pezzella; Jean-Frédéric Blanc; Julien Edeline
PSMA immunohistochemistry as a diagnostic biomarker of hepatocellular carcinoma

PSMA免疫组织化学作为肝细胞癌的诊断生物标志物

JHEP Reports
IF7.5
2025-07-310
OAAI
Killian Véron; Etienne Becht; Astrid Laurent-Bellue; Rémy Nicolle; Miguel Albuquerque; Samira Laouirem; Hélène Cazier; Clément Bailly; Mohamed Bouattour; Mickaël Lesurtel; Catherine Guettier; Rachida Lebtahi; Valérie Vilgrain; Valérie Paradis; Jérôme Cros; Aurélie Beaufrère
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

瑞戈非尼联合改良吉西他滨-奥沙利铂方案治疗晚期胆道癌。BREGO研究（随机 Ib/II 期）。

ONCOLOGIST
IF4.2
2025-06-010
OAAI
Blanc, Jean-Frederic; Bouattour, Mohamed; Gauthier, Ludovic; Deshayes, Emmanuel; Guillemard, Sophie; Touchefeu, Yann; Portales, Fabienne; Borg, Christophe; Harguem, Lobna; Guimbaud, Rosine; Mineur, Laurent; Ychou, Marc; Mazard, Thibault; Assenat, Eric
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study

度伐鲁单抗联合化疗在晚期胆道癌中的应用：III期TOPAZ-1研究的3年总生存期更新

Journal of Hepatology
IF33
2025-05-150
OAAI
Do-Youn Oh; Aiwu Ruth He; Shukui Qin; Li-Tzong Chen; Takuji Okusaka; Jin Won Kim; Thatthan Suksombooncharoen; Myung Ah Lee; Masayuki Kitano; Howard A. Burris; Mohamed Bouattour; Suebpong Tanasanvimon; Renata Zaucha; Antonio Avallone; Juan Cundom; Aleksandra Kuzko; Julie Wang; Ioannis Xynos; Arndt Vogel; Juan W. Valle
Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort

对纤维层状癌的全身性治疗反应与生存：一项法国AGEO-SFCE多中心回顾性队列研究

Digestive and Liver Disease
IF3.8
2025-05-010
OAAI
Xixi Ye-Tran; Mohamed Bouattour; Brice Fresneau; Anthony Turpin; Audrey Perret; Carole Vitellius; Romain Coriat; Jean Frederic Blanc; Marie Lequoy; Hélène Regnault; Daniel Pietrasz; David Sefrioui; Thierry Lecomte; Emilie Moati; Olivier Caliez; Eric Nguyen-Khac; Thomas Walter; Vincent Hautefeuille

研究方向

暂未获取到该数据
M
Maxime Ronot
H 指数:55论文数:598被引数:1.1万
V
Valérie Vilgrain
H 指数:98论文数:883被引数:4.7万
V
Valérie Paradis
H 指数:98论文数:844被引数:4.3万
S
Sandrine Faivre
H 指数:69论文数:505被引数:2.0万
J
Julien Edeline
H 指数:52论文数:394被引数:1.8万
É
Éric Raymond
H 指数:78论文数:595被引数:2.9万
F
François Cauchy
H 指数:39论文数:345被引数:6,009
A
Aurélie Bèaufrere
H 指数:20论文数:124被引数:1,576
C
Christian Hobeika
H 指数:20论文数:150被引数:1,248
J
Jean‐Charles Nault
H 指数:63论文数:369被引数:1.9万